Gillian McGovern is an associate editor at Pharmacy Times®. She graduated from Rowan University in 2023 with a BA in Writing Arts and concentrations in Publishing & Writing for the Public, Technical & Professional Writing, and Creative Writing.
FDA Grants Fast Track Designation for AC699 for Patients With ER+/HER2– Breast Cancer
August 15th 2024AC699 is being evaluated for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2–), estrogen receptor 1-mutated advanced or metastatic breast cancer with disease progression on or after at least 1 line of endocrine-based therapy.
Read More
FDA Approves Vorasidenib for Adults, Pediatric Patients With Grade 2 Astrocytoma, Oligodendroglioma
August 7th 2024This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.
Read More